Monopar Therapeutics (MNPR) Leases (2022 - 2025)

Quarterly results put Leases at $254921.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $254921.0 (changed N/A YoY), and the annual figure for FY2025 was $254921.0, changed.

Monopar Therapeutics has reported Leases over the past 3 years, most recently at $254921.0 for Q4 2025.

  • Leases reached $254921.0 in Q4 2025 per MNPR's latest filing, up from $106666.0 in the prior quarter.
  • Across five years, Leases topped out at $254921.0 in Q4 2025 and bottomed at $9102.0 in Q1 2025.
  • Median Leases over the past 3 years was $57461.0 (2022), compared with a mean of $73789.4.
  • Peak annual rise in Leases hit 8.04% in 2023, while the deepest fall reached 79.35% in 2023.
  • Over 3 years, Leases stood at $61228.0 in 2022, then tumbled by 79.35% to $12646.0 in 2023, then surged by 1915.82% to $254921.0 in 2025.
  • Business Quant data shows Leases for MNPR at $254921.0 in Q4 2025, $106666.0 in Q3 2025, and $118170.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 83,048.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - 61,822.50
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 285.20 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 1.69 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 189.30 Mn
10 Monopar Therapeutics 466.82 Mn 466.82 Mn - 254,921.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 254,921.00
Sep 30, 2025 106,666.00
Jun 30, 2025 118,170.00
Mar 31, 2025 9,102.00
Dec 31, 2023 12,646.00
Sep 30, 2023 25,088.00
Jun 30, 2023 37,330.00
Mar 31, 2023 49,376.00
Dec 31, 2022 61,228.00
Sep 30, 2022 72,889.00
Jun 30, 2022 84,363.00
Mar 31, 2022 53,694.00